BioPharma Resources

Drug Trial Radar · NCT07144345

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

Randomized, Multi-Center, Evaluator-Blind, Vehicle-Controlled Study to Evaluate Efficacy and Safety of Reformulated Levulan Kerastick Plus Photodynamic Therapy (PDT) for Field-Directed Treatment in Patients With Actinic Keratosis (AK) of Face and (Bald) Scalp

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Nov 19, 2025

Primary completion

Jan 2027

Study completion Apr 2027

Sponsor

Sponsor type
Industry
First posted
Aug 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled study evaluates the efficacy and safety of reformulated Levulan Kerastick (aminolevulinic acid HCl 20%) combined with photodynamic therapy (PDT) for field-directed treatment of actinic keratosis (AK) on the face or bald scalp. Approximately 160 adult patients with 4-8 mild to moderate AK lesions will be randomized into four treatment arms based on two variables: type of treatment (active drug or vehicle) and incubation time. During the study, up to 2 PDT sessions may be administered depending on the clearance of lesions. The primary endpoint is complete clearance rate (CCR) at Week 12. Secondary endpoints include AK clearance rate (AKCR), partial clearance, change in total lesion count and area, recurrence rate, cosmetic response, and patient satisfaction. Safety assessments include adverse events, local skin reactions, vital signs, and lab tests.

Conditions

  • Actinic Keratosis

Interventions

  • Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Drug

    Solution for topical use

  • Vehicle containing excipients only (VEH) without active ingredientOther

    Solution for topical use

  • Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170EDevice

    BLU-U® blue light Photodynamic Therapy (PDT) illuminator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Clearance Rate (CCR) i.e., proportion of patients achieving complete clearance of all AK lesions in the Treatment Area.Time frame: Week 12

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Dermatology Clinical Research, Inc

    Fremont, California · Recruiting

  • Center for Clinical and Cosmetic Research

    Aventura, Florida · Recruiting

  • Arlington Dermatology

    Rolling Meadows, Illinois · Recruiting

  • The Indiana Clinical Trials Center, PC

    Plainfield, Indiana · Recruiting

  • Dermatologic Surgery Center of Washington

    Chevy Chase, Maryland · Recruiting

  • Minnesota Clinical Study Center

    New Brighton, Minnesota · Recruiting

  • Medisearch, LLC

    Saint Joseph, Missouri · Recruiting

  • Onsite Clinical Solutions, LLC

    Huntersville, North Carolina · Recruiting

  • Oregon Dermatology and Research Center

    Portland, Oregon · Recruiting

  • Palmetto Clinical Trial Services, LLC

    Greenville, South Carolina · Recruiting

  • Tennessee Clinical Research Center

    Nashville, Tennessee · Recruiting

  • Premier Clinical Research

    Spokane, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.